Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
Total Valuation
Fennec Pharmaceuticals has a market cap or net worth of $140.07M. The enterprise value is $229.47M.
Market Cap$140.07M
Enterprise Value$229.47M
Share Statistics
Fennec Pharmaceuticals has 27.59M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27.59M
Owned by Insiders1.70%
Owned by Instutions
Financial Efficiency
Fennec Pharmaceuticals’s return on equity (ROE) is 1.38 and return on invested capital (ROIC) is -66.06%.
Return on Equity (ROE)138.06%
Return on Assets (ROA)-59.73%
Return on Invested Capital (ROIC)-66.06%
Return on Capital Employed (ROCE)-66.13%
Revenue Per Employee$1,485,562.5
Profits Per Employee-$13,625
Employee Count32
Asset Turnover0.79
Inventory Turnover0.58
Valuation Ratios
The current PE Ratio of Fennec Pharmaceuticals is -18.93. Fennec Pharmaceuticals’s PEG ratio is 0.56.
PE Ratio-18.93
PS Ratio14.29
PB Ratio-26.13
Price to Fair Value-26.13
Price to FCF-17.72
Price to Operating Cash Flow-17.72
PEG Ratio0.56
Income Statement
In the last 12 months, Fennec Pharmaceuticals had revenue of $47.54M and earned -$436.00K in profits. Earnings per share was $0.06.
Revenue$47.54M
Gross Profit$44.35M
Operating Income$2.57M
Pretax Income-$71.00K
Net Income-$436.00K
EBITDA4.67M
Earnings Per Share (EPS)0.06
Cash Flow
In the last 12 months, operating cash flow was $26.98M and capital expenditures $0.00, giving a free cash flow of $26.98M billion.
Operating Cash Flow$26.98M
Free Cash Flow$26.98M
Free Cash Flow per Share$0.98
Dividends & Yields
Fennec Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-5.64%
Earnings Yield-5.28%
Stock Price Statistics
Beta1.18
52-Week Price Change-48.83%
50-Day Moving Average6.31
200-Day Moving Average5.74
Relative Strength Index (RSI)37.12
Average Volume (3m)117.22K
Important Dates
Fennec Pharmaceuticals upcoming earnings date is May 8, 2025, TBA.
Last Earnings DateMar 10, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Fennec Pharmaceuticals as a current ratio of 3.56, with Debt / Equity ratio of -2.66
Current Ratio3.56
Quick Ratio3.27
Debt to Market Cap0.10
Net Debt to EBITDA-1.43
Interest Coverage Ratio-3.76
Taxes
In the past 12 months, Fennec Pharmaceuticals has paid $1.40M in taxes.
Income Tax$1.40M
Effective Tax Rate0.00%
Enterprise Valuation
Fennec Pharmaceuticals EV to EBITDA ratio is -26.00, with an EV/FCF ratio of -18.75.
EV to Sales15.12
EV to EBITDA-26.00
EV to Free Cash Flow-18.75
EV to Operating Cash Flow-18.75
Balance Sheet
Fennec Pharmaceuticals has $26.63M in cash and marketable securities with $19.34M in debt, giving a net cash position of -$7.29M billion.
Cash & Marketable Securities$26.63M
Total Debt$19.34M
Net Cash-$7.29M
Net Cash Per Share-$0.26
Tangible Book Value Per Share-$0.44
Margins
Gross margin is 94.08%, with operating margin of -60.09%, and net profit margin of -75.50%.
Gross Margin94.08%
Operating Margin-60.09%
Pretax Margin-75.50%
Net Profit Margin-75.50%
EBITDA Margin-58.18%
EBIT Margin-59.53%
Analyst Forecast
The average price target for Fennec Pharmaceuticals is $14.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$14.00
Price Target Upside166.67%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast